Following a full submission
AWMSG advice |
|||
| Status: Not recommended | |||
Doxylamine succinate/pyridoxine hydrochloride (Xonvea®) is not recommended for use within NHS Wales for the treatment of nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management. The cost-effectiveness data presented in the submission were insufficient for AWMSG to recommend its use. |
|||
|
|||
Medicine details |
|||
| Medicine name | doxylamine succinate/pyridoxine hydrochloride (Xonvea®) | ||
| Formulation | 10 mg/10 mg film-coated tablet | ||
| Reference number | 2170 | ||
| Indication | Treatment of nausea and vomiting of pregnancy in those patients who do not respond to conservative management |
||
| Company | Alliance Pharmaceuticals Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Full | ||
| Status | Not recommended | ||
| Advice number | 0819 | ||
| NMG meeting date | 03/04/2019 | ||
| AWMSG meeting date | 15/05/2019 | ||
| Date of issue | 11/06/2019 | ||